European innovation initiative puts Novo, Sanofi, and Eli Lilly in the same room
Novo Nordisk is participating in a public-private, European initiative, under which the firm has to share data with some of its biggest competition. Being a partner and a competitor can be a balancing act, according to Novo VP Matthias Müllenborn.
by ulrich quistgaard, translated by daniel pedersen
Novo Nordisk sees clear advantages from being part of the new public-private, European partnership, dubbed the Innovative Health Initiative (IHI), which brings the EU and the life science industry closer to each other with a budget of EUR 2.4bn.